A Prospective, Single Arm, Open Label, Phase II Clinical Study on the Efficacy and Safety of Ivonescimab (AK112) Combined With TAS-102 in the Treatment of Refractory MSS/pMMR Advanced Colorectal Cancer

NCT06936488 · clinicaltrials.gov ↗

NA

Phase

ENROLLING_BY_INVITATION

Status

35

Enrollment

OTHER

Sponsor class

Conditions

MSS/pMMR Type Metastatic Colorectal Adenocarcinoma Patients

Interventions

DRUG: Ivonescimab,TAS-102

Sponsor

Huai'an First People's Hospital